Referring to the original post by "sdsurfin", Replicel said:
"For people with extensive baldness of many years duration, we will need to conduct a separate study. It is likely that extensive, long-term duration AGA will need different cell dosages and changes to the parameters of our injection device." They also state "our phase 2 clinical trial will be tested on people with thinning hair."
Since classic Norwood balding entails the progression of completely bald areas, it would seem that their treatment (at least in the current form which will be trialed for Phase 2) would not be effective in treating classic Norwood balding. Rather it sounds like the Phase 2 treatment would better serve diffuse patterned/unpatterned alopecia (DPA/DUPA), rather than classic Norwood balding.
This begs the question of why Replicel and/or Shiseido wouldn't conduct the subsequent study alluded to ("extensive, long-duration AGA") concurrently with their upcoming Phase 2 studies. One would assume that they actually have a very good idea of the mechanism associated with new follicle formation as a result of their treatment, at least in bald mice. The latest video from Shiseido showed a bald mouse with a "crown" of hair produced by an injection of RCH-01, so it seems silly to wait 39 months for the Phase 2 study to complete on "people with thinning hair" before tackling the fully bald problem. If they don't tackle the problem of fully bald areas, then it would seem that their solution to Norwood balding would come only years down the road.
Does anyone, especially I suppose "sdsurfin" have any input on this?
"For people with extensive baldness of many years duration, we will need to conduct a separate study. It is likely that extensive, long-term duration AGA will need different cell dosages and changes to the parameters of our injection device." They also state "our phase 2 clinical trial will be tested on people with thinning hair."
Since classic Norwood balding entails the progression of completely bald areas, it would seem that their treatment (at least in the current form which will be trialed for Phase 2) would not be effective in treating classic Norwood balding. Rather it sounds like the Phase 2 treatment would better serve diffuse patterned/unpatterned alopecia (DPA/DUPA), rather than classic Norwood balding.
This begs the question of why Replicel and/or Shiseido wouldn't conduct the subsequent study alluded to ("extensive, long-duration AGA") concurrently with their upcoming Phase 2 studies. One would assume that they actually have a very good idea of the mechanism associated with new follicle formation as a result of their treatment, at least in bald mice. The latest video from Shiseido showed a bald mouse with a "crown" of hair produced by an injection of RCH-01, so it seems silly to wait 39 months for the Phase 2 study to complete on "people with thinning hair" before tackling the fully bald problem. If they don't tackle the problem of fully bald areas, then it would seem that their solution to Norwood balding would come only years down the road.
Does anyone, especially I suppose "sdsurfin" have any input on this?
Comment